User contributions for Wowbagger2
A user with 81 edits. Account created on 18 September 2017.
15 December 2017
- 13:1013:10, 15 December 2017 diff hist −539 User:Wowbagger2/sandbox No edit summary
- 12:1312:13, 15 December 2017 diff hist −1,793 User:Wowbagger2/sandbox No edit summary
- 09:2709:27, 15 December 2017 diff hist +37 Copanlisib Added trade name in chembox Tags: Mobile edit Mobile web edit
- 09:2009:20, 15 December 2017 diff hist +1 Copanlisib →Regulatory history: Added full stop in regulator history section Tags: Mobile edit Mobile web edit
- 03:2603:26, 15 December 2017 diff hist +2,688 Copanlisib Added recent drug approval information in the US, including basic information on the drug label (including references to FDA pages)
- 03:0403:04, 15 December 2017 diff hist −5 User:Wowbagger2/sandbox No edit summary
- 03:0203:02, 15 December 2017 diff hist +1 User:Wowbagger2/sandbox No edit summary
- 03:0103:01, 15 December 2017 diff hist +360 User:Wowbagger2/sandbox No edit summary
- 02:4402:44, 15 December 2017 diff hist +154 User:Wowbagger2/sandbox →Regulatory history
- 02:3802:38, 15 December 2017 diff hist +549 User:Wowbagger2/sandbox No edit summary
- 02:1702:17, 15 December 2017 diff hist +23 User:Wowbagger2/sandbox →Mode of Action
- 02:1302:13, 15 December 2017 diff hist +544 User:Wowbagger2/sandbox No edit summary
- 01:5501:55, 15 December 2017 diff hist +1,042 User:Wowbagger2/sandbox No edit summary
- 00:3500:35, 15 December 2017 diff hist +1,061 User:Wowbagger2/sandbox No edit summary
14 December 2017
- 23:4923:49, 14 December 2017 diff hist +485 N User:Wowbagger2/sandbox ←Created page with '{{User sandbox}} <!-- EDIT BELOW THIS LINE --> '''Copanlisib''' (trade name '''Aliqopa''', {{respell|AL|ih|KO|pah}},<ref>http://labeling.bayerhealthcare.com/html...'
3 October 2017
- 23:0023:00, 3 October 2017 diff hist +560 P110α Added new sectionon Pharmacolgy and added recent drug approval for Copanlisib
- 22:5822:58, 3 October 2017 diff hist −553 P110α Undid revision 803674229 (had not provided an edit summary)
- 22:5522:55, 3 October 2017 diff hist +553 P110α No edit summary
- 22:4622:46, 3 October 2017 diff hist +507 P110δ →Pharmacology: Added approval of Copanlisib (an alpha/delta inhibitor)
- 22:2022:20, 3 October 2017 diff hist +60 Phosphoinositide 3-kinase inhibitor →Late stage: Apart from CLL Phase 3 studies, found only one (non-terminated) Phase 3 study (in follicular lymphoma)
- 22:0722:07, 3 October 2017 diff hist −21 Phosphoinositide 3-kinase inhibitor →Late stage: I removed the reference bound to 'Idelalisib for NHL', as neither of the mentioned studies there (entospletinib and GS-4059 combos with Idelalisib) is in Phase 3 studies (acc. to clintrials.gov)
- 21:4921:49, 3 October 2017 diff hist +85 Talk:Phosphoinositide 3-kinase →Phosphatidylinositol 3-kinase or Phosphoinositide 3-kinase
- 21:3321:33, 3 October 2017 diff hist +548 Phosphoinositide 3-kinase inhibitor Added FDA approval of Copanlisib for adults with Follicular lympoma (after two prior therapies)
23 September 2017
- 22:2522:25, 23 September 2017 diff hist +215 Copanlisib Undid revision 802079437 by Wowbagger2 (talk)
- 22:2222:22, 23 September 2017 diff hist +43 m Copanlisib Undid revision 802082497 by Wowbagger2 (talk)
- 21:5621:56, 23 September 2017 diff hist −43 Copanlisib Add links to b cell and PI3K. Tags: Mobile edit Mobile web edit
- 21:3121:31, 23 September 2017 diff hist −215 Copanlisib Added information on approval status, indication, mode of action and trade name in the US. Did not provide any update to the 'chembox' or the clinical trials part. Tags: Mobile edit Mobile web edit
21 September 2017
- 20:1620:16, 21 September 2017 diff hist +74 m Talk:Copanlisib →Accelerated approval by US FDA (as Aliqopa)
- 20:1220:12, 21 September 2017 diff hist 0 Talk:Copanlisib →Accelerated approval in the US (as Aliqopa)
- 20:1120:11, 21 September 2017 diff hist +2 Talk:Copanlisib →Accerated approval in the US (as Aliqopa)
- 20:0920:09, 21 September 2017 diff hist +318 Talk:Copanlisib →Accerated approval in the US (as Aliqopa): new section Tags: Mobile edit Mobile web edit
